Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Underwriters in $138 Million Stock Offering by Repligen

August 10, 2017

NEW YORKCovington advised the underwriters in a $138 million follow-on public offering of common stock by Repligen Corporation. Covington previously represented the underwriters in Repligen's $115 million convertible note offering in May 2016.

Repligen is a bioprocessing company focused on the manufacture of Protein A ligands, cell culture growth factors, and filtration and chromatography products used by life science companies to manufacture and purify biologic drugs such as monoclonal antibodies, recombinant proteins, and vaccines.

The Covington corporate team was led by Don Murray, Brian Rosenzweig, Matt Gehl, and John Mei.


Share this article: